<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321981</url>
  </required_header>
  <id_info>
    <org_study_id>MCLA-128-CL02</org_study_id>
    <secondary_id>2017-002821-39</secondary_id>
    <nct_id>NCT03321981</nct_id>
  </id_info>
  <brief_title>MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer</brief_title>
  <official_title>Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merus N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncology Therapeutic Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merus N.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label, multicenter international study will be performed to evaluate the
      efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two
      in Cohort 1 and one in Cohort 2.

      MCLA-128 is given in combinations in two metastatic breast cancer (MBC) populations,
      HER2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low HER2 expression
      (Cohort2).

      Two combinations treatments will be evaluated in Cohort 1, the doublet and triplet. Initially
      MCLA-128 is given in combination with trastuzumab in the doublet. After the safety of the
      doublet has been assessed in 4-6 patients, MCLA-128 is given in combination with trastuzumab
      and vinorelbine in the triplet, in parallel to the efficacy expansion of the doublet.

      The doublet and triplet combinations are both evaluated in two steps with an initial safety
      run-in followed by a cohort efficacy expansion. In total up to 40 patients evaluable for
      efficacy are included in both the doublet and triplet.

      In Cohort 2 MCLA-128 is administered in combination with the same previous endocrine therapy
      on which progressive disease is radiologically documented. A total of up to 40 patients
      evaluable for efficacy are included in the Cohort 2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of patients with a best overall response of Complete Response, Partial Response or Stable Disease at 24 weeks based upon RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline, every 6 weeks until progression up to one year after last patient first treatment</time_frame>
    <description>the time from treatment start until radiologic progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline, every 6 weeks until progression up to one year after last patient first treatment</time_frame>
    <description>the proportion of patients with overall response of Complete Response or Partial Response based upon RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline, every 6 weeks until progression up to one year after last patient first treatment</time_frame>
    <description>the time from response (Complete Response or Partial Response) until progression or death due to underlying cancer based upon RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every 3 months after last visit up to 1 year after last patient first treatment</time_frame>
    <description>the time from treatment start until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with treatment emergent Adverse Events (AE)</measure>
    <time_frame>continuous until 1 year after last patient last treatment</time_frame>
    <description>Evaluation of number of participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that discontinue due to intolerability of study drug</measure>
    <time_frame>continuous through study completion, an average of 6 months</time_frame>
    <description>discontinuations due to AEs, dose modifications due to AEs and immunogenicity assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration [Cmax]</measure>
    <time_frame>baseline and 3-12 weeks until last patient last treatment</time_frame>
    <description>maximum plasma concentration [Cmax] for MCLA-128 as measured from all individual plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trough plasma concentration [C0h]</measure>
    <time_frame>baseline and 3-12 weeks until last patient last treatment</time_frame>
    <description>plasma concentration of MCLA-128 as measured at trough level t=0h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve [AUC]</measure>
    <time_frame>baseline and 3-12 weeks until last patient last treatment</time_frame>
    <description>area under the concentration curve [AUC] for MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance [CL]</measure>
    <time_frame>6 weeks</time_frame>
    <description>clearance [CL] of MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution at steady state [Vss]</measure>
    <time_frame>6 weeks</time_frame>
    <description>volume of distribution at steady state [Vss] of MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum concentration [tmax]</measure>
    <time_frame>6 weeks</time_frame>
    <description>time to reach maximum concentration [tmax] for MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half life [t1/2]</measure>
    <time_frame>6 weeks</time_frame>
    <description>half life [t1/2] of MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of trastuzumab at end of infusion [C EOI]</measure>
    <time_frame>6 weeks</time_frame>
    <description>concentration of trastuzumab at end of infusion [C EOI]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trough plasma concentration [C0h] trastuzumab</measure>
    <time_frame>6 weeks</time_frame>
    <description>plasma concentration of trastuzumab as measured at trough level t=0h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug antibodies serum titers</measure>
    <time_frame>baseline and 6-12 weeks until last patient last treatment</time_frame>
    <description>serum titers of anti-drug antibodies against MCLA-128</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cohort 1 doublet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two step evaluation with safety review after 4-6 patients receiving combination of MCLA-128, 750mg 2hour intravenous infusion in combination with trastuzumab, 8mg/kg first cycle, 6mg/kg other cycles, 90minute intravenous infusion; once per cycle of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two step evaluation with safety review after 4-6 patients receiving combination of MCLA-128, 750mg 2hour intravenous infusion once per cycle of 21 days in combination with trastuzumab, 8mg/kg 90minute first cycle, 6mg/kg other cycles, intravenous infusion once per cycle of 21 days and vinorelbine, 25 mg/M2 10minute intravenous infusion twice per cycle of 21 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCLA-128, 750mg 2hour intravenous infusion once per cycle of 21 days in combination with same dose and regimen of endocrine therapy prior to study entry and on which the patient progressed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCLA-128</intervention_name>
    <description>full length IgG1 bispecific antibody targeting HER2 and HER3</description>
    <arm_group_label>Cohort 1 doublet</arm_group_label>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>bispecific</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>humanised IgG1 monoclonal antibody</description>
    <arm_group_label>Cohort 1 doublet</arm_group_label>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>antineoplastic drug of vinca alkaloid family</description>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <other_name>Navelbine</other_name>
    <other_name>vinorelbine tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>same endocrine therapy is administered as the last line of endocrine therapy</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>fulvestrant</other_name>
    <other_name>exemestane</other_name>
    <other_name>letrozole</other_name>
    <other_name>anastrazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent before initiation of any study procedures.

          2. Women with histologically or cytologically confirmed breast cancer with evidence of
             metastatic or locally advanced disease not amenable to any local therapy with curative
             intent.

          3. Measurable disease as defined by RECIST version 1.1 by radiologic methods on or after
             the most recent line of therapy. For Cohort 2, imaging must be available for central
             review.

          4. Eastern Cooperative Oncology Group performance status of 0 or 1.

          5. Life expectancy of ≥ 12 weeks, as per investigator.

          6. Left ventricular ejection fraction ≥ 50% by echocardiogram or multiple gated
             acquisition scan.

          7. Patients must have adequate organ function

        Exclusion Criteria:

          1. Central nervous system metastases that are untreated or symptomatic, or require
             radiation, surgery, or continued steroid therapy to control symptoms within 14 days of
             study entry.

          2. Known leptomeningeal involvement.

          3. Advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening
             complications in the short term.

          4. Participation in another interventional clinical trial or treatment with any
             investigational drug within 4 weeks prior to study entry.

          5. Any systemic anticancer therapy within 3 weeks of the first dose of study treatment.
             For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and
             nitrosoureas, or anticancer immunotherapies, a washout period of 6 weeks is required.
             For patients in Cohort 2, this does not apply to the most recently received hormone
             therapy.

          6. Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.
             Patients who received prior radiotherapy to ≥ 25% of bone marrow are not eligible,
             irrespective of when it was received.

          7. Persistent grade &gt; 1 clinically significant toxicities related to prior antineoplastic
             therapies (except for alopecia); stable sensory neuropathy ≤ grade 1 NCI-CTCAE v. 4.0
             is allowed.

          8. History of prior ≥ grade 3 hypersensitivity reaction or any toxicity attributed to
             trastuzumab or murine proteins that warranted permanent cessation of these agents
             (applicable for Cohort 1 only).

          9. Previous exposure to vinorelbine (applicable for Cohort 1 triplet combination only)

         10. Chronic use of high-dose oral corticosteroid therapy .

         11. Uncontrolled hypertension or unstable angina.

         12. History of congestive heart failure of Class II-IV New York Heart Association (NYHA)
             criteria, or serious cardiac arrhythmia requiring treatment (except atrial
             fibrillation, paroxysmal supraventricular tachycardia).

         13. History of myocardial infarction within 6 months of study entry.

         14. History of prior or concomitant malignancies (other than excised non-melanoma skin
             cancer or cured in situ cervical carcinoma) within 3 years of study entry.

         15. Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen
             therapy.

         16. Current serious illness or medical conditions including, but not limited to
             uncontrolled active infection, clinically significant pulmonary, metabolic or
             psychiatric disorders.

         17. Known HIV, HBV, or HCV infection.

         18. Pregnant or lactating women; women of childbearing potential must use effective
             contraception methods prior to study entry, for the duration of study participation,
             and for 6 months after the last dose of MCLA-128.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director: Ernesto Wasserman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merus N.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ernesto Wasserman, MD</last_name>
    <phone>+31302538800</phone>
    <email>enquiries@merus.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andres L Sirulnik, MD PhD</last_name>
    <phone>+31 30 2538800</phone>
    <email>enquiries@merus.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Mita, MD</last_name>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bill Gradishar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bill Gradishar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephany Graff, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephany Graff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hamilton, MD</last_name>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe AFTIMOS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe AFTIMOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi (GHdC)</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc CANON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Luc CANON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans WILDIERS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hans WILDIERS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne BLOCKMANS</last_name>
      <email>marianne.blockmans@hap.be</email>
    </contact>
    <contact_backup>
      <last_name>David MAYNE</last_name>
      <email>David.Mayne@hap.be</email>
    </contact_backup>
    <investigator>
      <last_name>Nathalie CORNEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine BARGOT-GUGLIELMETTI</last_name>
      <email>c1guglielmetti@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Fernando BAZAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas BACHELOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas BACHELOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony GONCALVEZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony GONCALVEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois-Clement BIDARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francois-Clement BIDARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PETIT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry PETIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DALENC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florence DALENC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara PISTILLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Barbara PISTILLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Champalimaud Clinical Centre</name>
      <address>
        <city>Lisbon</city>
        <zip>1400-038</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuela Seixas, Dr.</last_name>
      <email>manuela.seixas@fundacaochampalimaud.pt</email>
    </contact>
    <investigator>
      <last_name>Fatima Cardoso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopistal San Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noemia Afonso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noemia Afonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Português Oncologia</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Ferreira, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Ferreira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall D'Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Maines</last_name>
    </contact>
    <investigator>
      <last_name>Cristina SAURA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic. C/Villaroel</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Jesus VIDAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Jesus VIDAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther HOLGADO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Esther HOLGADO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis MANSO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis MANSO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquin GAVILA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquin GAVILA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bispecific Antibody IgG1, HER2 HER3</keyword>
  <keyword>MCLA-128</keyword>
  <keyword>Antibodies, bispecific</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Cytokines</keyword>
  <keyword>combination Trastuzumab with and without Vinorelbine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>individual participant data are made available only to the individual patient upon specific request of that individual patient or its treating physician</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

